8-K 1 wst-q32014form8k.htm 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) – October 29, 2014

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania |  | 1-8036 |  | 23-1210010
(State or other jurisdiction of Incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA |  |  |  | 19341-0645
(Address of principal executive offices) |  |  |  | (Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.
On October 30, 2014, West Pharmaceutical Services, Inc. (Company) issued a press release announcing its financial results for the third quarter ended September 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.
A copy of the Company’s presentation materials used during the call will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 8.01 Other Events.
On October 29, 2014, the Company’s Board of Directors authorized the repurchase of up to $100 million of the Company’s common stock from time to time on the open market or in privately negotiated transactions as permitted under Securities Exchange Act of 1934 Rule 10b-18. The extent to which West repurchases its shares and the timing of any repurchases of common stock will be determined by West management based on its evaluation of market conditions and other factors. The program is expected to be completed no later than December 31, 2015.
Item 9.01 Financial Statements and Exhibits.

(d) | Exhibits |
| Exhibit 99.1 | West Pharmaceutical Services, Inc. Press Release, dated October 30, 2014.
| Exhibit 99.2 | West Pharmaceutical Services, Inc. Presentation Slides.

2

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| WEST PHARMACEUTICAL SERVICES, INC. |
| /s/ William J. Federici |
| William J. Federici |
| Senior Vice President and Chief Financial Officer |
October 30, 2014 |  |

3

EXHIBIT INDEX

Exhibit No. |  | Description
99.1 |  | West Pharmaceutical Services, Inc. Press Release, dated October 30, 2014.
99.2 |  | West Pharmaceutical Services, Inc. Presentation Slides.

4